Erika M. Lisabeth - Concepedia

Author

Erika M. Lisabeth

Also Known As

E. M. Lisabeth, E.M. Lisabeth, EM Lisabeth, Erika Cione, Erika Lisabeth, Erika M Lisabeth, Erika M. Lisabeth, Erika Mathes Lisabeth

Publications

1.1K

Citations

H-Index

Concepts

All Affiliations

Michigan State University University of Michigan University of California San Diego Sanford Burnham Prebys Medical Discovery Institute

About

Erika M. Lisabeth is an author at Michigan State University specializing in radiation oncology, medicine, and tumor biology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	4	4	212
2	Cell Biology	3	3	156
3	Immunology	1	1	56
4	Pharmacology	1	1	56
5	Cancer Cell Biology	1	1	27

Erika M. Lisabeth

Publications

519

Citations

H-Index

Page 1

	Year	Citations
Cancer Somatic Mutations Disrupt Functions of the EphA3 Receptor Tyrosine Kinase through Multiple Mechanisms Erika M. Lisabeth, C. Fernández, Elena B. Pasquale Biochemistry Cancer ResearchSystems BiologySomatic VariantMultiple MechanismsMedicine	2012	71
Local delivery of novel MRTF/SRF inhibitors prevents scar tissue formation in a preclinical model of fibrosis Cynthia Yu‐Wai‐Man, Bradley Spencer‐Dene, Richard M. H. Lee, Scientific Reports	2017	64
Rho-mediated signaling promotes BRAF inhibitor resistance in de-differentiated melanoma cells Sean A. Misek, Kate M. Appleton, Thomas S. Dexheimer, Oncogene Cell RegulationMedicineMelanomaDe-differentiated Melanoma CellsCell Biology	2019	58
Pharmacokinetic optimitzation of CCG-203971: Novel inhibitors of the Rho/MRTF/SRF transcriptional pathway as potential antifibrotic therapeutics for systemic scleroderma Kim Hutchings, Erika M. Lisabeth, Walajapet G. Rajeswaran, Bioorganic & Medicinal Chemistry Letters Pharmacokinetic OptimitzationSystemic SclerodermaMedicineImmunologyRho/mrtf/srf Transcriptional Pathway	2017	56
Attenuation of Eph Receptor Kinase Activation in Cancer Cells by Coexpressed Ephrin Ligands Giulia Falivelli, Erika M. Lisabeth, Elena Rubio de la Torre, PLoS ONE	2013	55
Identification of Pirin as a Molecular Target of the CCG-1423/CCG-203971 Series of Antifibrotic and Antimetastatic Compounds Erika M. Lisabeth, Dylan Kahl, Indiwari Gopallawa, ACS Pharmacology & Translational Science	2019	46
Pharmacological Inhibition of Myocardin-related Transcription Factor Pathway Blocks Lung Metastases of RhoC-Overexpressing Melanoma Andrew J. Haak, Kathryn M. Appleton, Erika M. Lisabeth, Molecular Cancer Therapeutics	2016	45
5-Aryl-1,3,4-oxadiazol-2-ylthioalkanoic Acids: A Highly Potent New Class of Inhibitors of Rho/Myocardin-Related Transcription Factor (MRTF)/Serum Response Factor (SRF)-Mediated Gene Transcription as Potential Antifibrotic Agents for Scleroderma Dylan Kahl, Kim Hutchings, Erika M. Lisabeth, Journal of Medicinal Chemistry	2019	40
Small-Molecule Inhibition of Rho/MKL/SRF Transcription in Prostate Cancer Cells: Modulation of Cell Cycle, ER Stress, and Metastasis Gene Networks Chris R. Evelyn, Erika M. Lisabeth, Susan M. Wade, Microarrays Rho/mkl/srf TranscriptionEr StressCancer BiologyTumor BiologyTranscriptional Regulation	2016	27
The Rho/MRTF pathway inhibitor CCG-222740 reduces stellate cell activation and modulates immune cell populations in KrasG12D; Pdx1-Cre (KC) mice Ana S. Leal, Sean A. Misek, Erika M. Lisabeth, Scientific Reports	2019	26

Page 1